Meridian Bioscience (VIVO) Tops Q2 EPS by 35c

Meridian Bioscience (NASDAQ: VIVO) reported Q2 EPS of $0.67, $0.35 better than the analyst estimate of $0.32. Revenue for the quarter came in at $111.2 million versus the consensus estimate of $83.29 million.

GUIDANCE:

Meridian Bioscience sees FY2022 EPS of $1.30-$1.40, versus the consensus of $1.37. Meridian Bioscience sees FY2022 revenue of $330-345 million, versus the consensus of $337 million.

For earnings history and earnings-related data on Meridian Bioscience (VIVO) click here.

You May Also Be Interested In

• H&R Block (HRB) Tops Q4 EPS by 7c, Offers Guidance
• Canterbury Park (CPHC) Misses Q2 EPS by 3c
• Immunome, Inc. (IMNM) Reports Q2 Loss of $0.65